Instil Bio Q2 net loss narrows to $4.3 million from $21.4 million a year earlier
Instil Bio reported a second-quarter 2026 net loss of $4.3 million, or $0.63 per share, down from $21.4 million, or $3.24 per share, a year earlier. The company had $69.9 million in cash and marketable securities at June 30, 2026, down from $76.3 million at December 31, 2025, and expects that balance to fund its operating plan beyond 2027. Shareholders are seeing a much smaller loss, but the company is also evaluating acquisitions and in-licensing deals that could change its spending.
Key points
- Q2 2026 net loss was $4.3 million ($0.63 per share), versus $21.4 million ($3.24 per share) in Q2 2025.
- In-process R&D expense was nil in Q2 2026, compared with $10.0 million in Q2 2025.
- Cash, cash equivalents, restricted cash and marketable securities were $69.9 million at June 30, 2026, versus $76.3 million at December 31, 2025.
- Instil is evaluating potential acquisitions, in-licensing and related opportunities.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.